RYTM early HO launch momentum and Prader-Willi plans drive growth
The conference cited strong early momentum in the HO launch, broad prescriber engagement and favorable payer dynamics. It also highlighted Prader-Willi syndrome as a major strategic focus, with robust Phase II data and plans for Phase III trials.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.